Spatial Genomics is a developer of sequential fluorescence in situ hybridization (seqFISH) technology.
Spatial Genomics has raised $56.0M in total funding. The most recent round was Series A. The last funding was announced in February 2022.
Spatial Genomics's investors include Fulgent Therapeutics, 12 West Capital.
Spatial Genomics is headquartered in Pasadena, United States.
Spatial Genomics is a developer of sequential fluorescence in situ hybridization (seqFISH) technology.
Spatial Genomics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spatial Genomics — Funding & Investors." VCBacked, February 23, 2022, https://www.vcbacked.co/company/spatial-genomics. Accessed September 30, 2026.
VCBacked. (2022). Spatial Genomics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/spatial-genomics
{{cite web |title=Spatial Genomics — Funding & Investors |url=https://www.vcbacked.co/company/spatial-genomics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated